Abstract
Immune checkpoint inhibitors (ICIs) are a promising class of anticancer drugs associated with immune-related adverse events (IRAEs). In registration studies of selected cancer populations, neurologic IRAEs were rare. Post-marketing experience describing their prevalence in clinical practice continues to be reported. A retrospective cohort of patients treated at our institution with ICIs from 2005 to 2017 was identified. Patients with new neurologic ICD codes documented during or after ICI treatment were enrolled. Comprehensive medical record review identified patients with neurologic IRAEs causally linked to ICIs. This study focused on CTCAE grade 2-4 IRAEs. 526 patients were screened; 55 candidate patients were identified; 5 cases met criteria for neurologic IRAEs, an incidence of 0.95% (n = 5/526). IRAEs identified were transverse myelopathy, demyelinating sensorimotor polyneuropathy, oculomotor nerve palsy, sensory neuropathy, and posterior reversible encephalopathy syndrome. ICIs were held in three patients, rechallenged in one, and dose-reduced in one. Corticosteroids were given in three patients, and response varied from complete symptom resolution to minimal response and ultimately death. Other treatments were based on I...Continue Reading
References
Dec 29, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michela MaurPierfranco Conte
Apr 5, 2015·The Lancet Oncology·Alexander M M EggermontAlessandro Testori
Apr 22, 2015·The New England Journal of Medicine·Michael A PostowF Stephen Hodi
Sep 29, 2015·The New England Journal of Medicine·Hossein BorghaeiJulie R Brahmer
Jan 9, 2017·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S CuzzubboA F Carpentier
May 13, 2017·The Oncologist·James LarkinDavid A Reardon
Citations
Oct 20, 2018·Future Oncology·Nicole A Carreau, Anna C Pavlick
Feb 23, 2019·American Journal of Hematology·Rebecca Karp LeafDavid E Leaf
Mar 14, 2019·Journal of the National Comprehensive Cancer Network : JNCCN·John A ThompsonJillian L Scavone
Nov 9, 2019·Journal of Neurology·M De GrootD Brandsma
Aug 14, 2019·Neurology·Divyanshu DubeyAmanda C Guidon
Sep 8, 2020·Asia-Pacific Journal of Clinical Oncology·Siyuan FanHongzhi Guan
Oct 28, 2018·International Journal of Molecular Sciences·Puja Sharma, Waldemar Debinski
Feb 14, 2020·JCI Insight·Jolien WolbertMaureen A Su
Feb 2, 2019·Annals of Intensive Care·Virginie LemialeUNKNOWN Groupe de Recherche en Reanimation Respiratoire du patient d’Onco-Hématologie (Grrr-OH)
Jul 1, 2020·Current Neurology and Neuroscience Reports·Jigisha P ThakkarRimas V Lukas
Sep 11, 2020·Journal of Neurology·Kensuke OkadaShigeaki Suzuki
Aug 17, 2020·Neurology·Elia SechiAnastasia Zekeridou
Jan 30, 2019·Surgical Oncology·Nicole Carreau, Anna Pavlick
Jan 12, 2021·IJU Case Reports·Toshiki OkaKazuo Nishimura
Dec 29, 2020·Expert Opinion on Therapeutic Targets·Jennifer E KimChristopher M Jackson
Nov 12, 2020·Eye and Brain·Caberry W YuJonathan A Micieli
Jun 2, 2020·Critical Reviews in Oncology/hematology·Ioannis ParthymosMatilda Florentin
Apr 1, 2021·Drugs·Blake H FortesLauren A Dalvin
Mar 4, 2021·Neurology·Alessandro MariniAlberto Vogrig
Apr 27, 2021·Frontiers in Neurology·Cristina Valencia-Sanchez, Anastasia Zekeridou
Sep 11, 2021·Frontiers in Immunology·Lin Zhou, Xin Wei
Oct 16, 2021·Brain Communications·Léo PlaçaisCécile Cauquil
Dec 16, 2020·Neurology·Alberto VogrigJérôme Honnorat